** Shares of biotech firm AC Immune ACIU.O rise 8% to $3.35 premarket
** Co says early-stage trial shows its PET imaging agent can detect TDP‑43, a harmful protein linked to several brain diseases
** TDP‑43 buildup is seen in conditions such as frontotemporal dementia, a disease that damages personality and language, and ALS, which affects nerve cells controlling muscles - ACIU
** Co says patients with a genetic form of frontotemporal dementia showed higher tracer uptake in expected brain regions than healthy volunteers
** Says imaging agent was well tolerated, with a safety profile suitable for further testing
** Adds final data from first part of study expected in H1 2026; further testing underway in patients with dementia-related conditions
** Shares rose ~16% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Comments